News Category
In vitro ADME studies are critical for early evaluation of drug candidates, helping to avoid costly late-stage failures and expedite the development o...
GeoVax's preclinical data demonstrate that a single dose of its next-generation MVA-X vaccine provides durable protection against highly pathogenic Cl...
Onco-Innovations is aligning its manufacturing, preclinical, and clinical planning efforts to move its lead cancer candidate ONC010 toward potential f...
VERAXA Biotech appoints Raju Willener as CFO, bringing over 30 years of capital markets experience to support the advancement of its BiTAC oncology pi...
Apimeds Pharmaceuticals US engages IBN to enhance corporate communications, aiming to raise investor awareness of its MindWave Innovations subsidiary'...
Regentis Biomaterials is advancing its lead product GelrinC for knee cartilage repair, with a U.S. pivotal trial underway and European commercializati...
Silo Pharma has received a Notice of Allowance from the USPTO for a patent covering its lead PTSD therapeutic SPC-15, reinforcing its intellectual pro...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, with early clinical data and a pi...
Med-X is expanding its Nature-Cide natural pest control brand and securing certifications as it prepares for a Nasdaq debut, potentially disrupting th...
Telomir Pharmaceuticals reports that Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines at similar low concentrations, supporting...
Quantum BioPharma's FDA clearance of its Lucid-MS IND allows the company to proceed directly to a Phase 2 trial in multiple sclerosis, potentially acc...
GeoVax has secured access to CEPI's Centralised Laboratory Network for independent testing of its MVA-based mpox vaccine candidate, GEO-MVA, in a pivo...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers engineer targeted and stimul...
Creative Biolabs has enhanced its single-cell multi-omics and RNA sequencing services to help researchers overcome sample processing challenges and un...
A new review reveals that the tumor microenvironment actively shapes natural killer cells into distinct subsets with specialized roles, offering a new...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, highlighting...
Regentis Biomaterials has treated 43 of 80 patients in its Phase III GelrinC trial and received European approval for a manufacturing process that inc...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug, receives FDA clearance for Phase 2 trial, potentially revolutionizing multiple ...
TransCode Therapeutics has named John Tattory as interim CFO after Tom Fitzgerald's retirement, bringing extensive financial and operational leadershi...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® technology and oncology...
Quantum BioPharma's Lucid-MS, a novel non-immune-suppressing multiple sclerosis therapy, advances toward Phase 2 trials after FDA IND clearance, poten...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS represents a historic shift in multiple sclerosis treatment, moving beyond immune su...
Quantum BioPharma receives FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and potent...
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP and uses two selectivity mechanisms...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially ...
American Fusion's Texatron program advances to active testing with record pressures and new analyst coverage, highlighting the potential of deuterium-...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing ENV-105 to reverse cancer drug re...
Nutriband's CEO participation at the Nasdaq LaB summit underscores the company's strategic positioning in the transdermal pharmaceutical market and it...
Silo Pharma's participation in the IPAC-RS 2026 forum underscores its commitment to advancing SPC-15, a nose-to-brain treatment for PTSD, with promisi...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant milestone for a novel approach to multiple sclerosis treatment, poten...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug candidate, has received FDA clearance to begin a Phase 2 trial, a rare milestone...
Helus Pharma's CEO participation in a major investment conference underscores the company's clinical advancements in psychedelic-inspired therapies fo...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to enhance supply diversity and preparedness.
Voyageur Pharmaceuticals has achieved the first milestone in its Bayer collaboration, securing a $1 million payment and advancing toward a domestic io...
Greenland Mines announced a Q4 2026 spin-off of its biotech division, received Nasdaq approval, completed the Sarfartoq acquisition, and reported a hi...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to strengthen its financial leadership and advance its oncology pipeline...
Scinai Immunotherapeutics strategically terminates its PC111 license with PinCell to concentrate on its NanoAb platform and CDMO business, aiming to p...
Onco-Innovations advances its oncology pipeline by building manufacturing readiness, IND-enabling activities, and financial support, reducing executio...
OS Animal Health's presentation at the Moody Capital Solutions Disruptive Growth & Life Sciences Conference highlights its progress in securing USDA c...
Quantum BioPharma's FDA clearance for Lucid-MS phase 2 trial introduces a first-in-class myelin repair approach that could transform MS treatment by p...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a historic step toward a first-in-class therapy targeting myelin repair, poten...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Pan African Clinical Trials Registry, marking a critical step in ...
Greenland Mines announces corporate milestones including a Q4 2026 biotech spin-off, Nasdaq compliance, and a $2.05 billion NPV assessment for its Sar...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug candidate for multiple sclerosis that targets...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial for Lucid-MS, a first-in-class drug targeting demyelination, signals a potential paradigm s...
Quantum BioPharma's FDA clearance to initiate a Phase 2 trial of Lucid-MS marks a pivotal step toward a targeted therapy for multiple sclerosis, poten...
